Join
Live feed
·
PRReleasevia Quantisnow
Monte Rosa Therapeutics Inc. logo

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
GLUE· Monte Rosa Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLUE (Monte Rosa Therapeutics Inc.) and more on Quantisnow.